

Cytomegalovirus Infection Treatment Market - 2023-2031

<https://marketpublishers.com/r/C314C95CB99DEN.html>

Date: November 2025

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: C314C95CB99DEN

Abstracts

The Cytomegalovirus Infection Treatment Market was valued at US\$ 516.36 million in 2023 and is anticipated to reach US\$ 858.65 million by 2031, at a CAGR of 0.067 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cytomegalovirus Infection Treatment Market.

This report delivers a comprehensive overview of the Cytomegalovirus Infection Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cytomegalovirus Infection Treatment Market. The Cytomegalovirus Infection Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Cytomegalovirus Infection Treatment Market Scope:

By Drug Type

Cytovene

Valcyte

Foscarnet

Vistide

Others

By Application

Stem Cell Transplantation

Organ Transplantation

Congenital CMV infection

Others

By Infection

Retinitis

Pneumonia

Esophagitis

Colitis

Others

By Diagnosis Test

Serologic Test

Polymerase Chain Reaction (PCR) Test

Others

By Route of Administration

Oral

Intravenous

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

Others

By End-User

Hospitals

Specialty Clinics

Homecare

Others

Key Players

Merck & Co., Inc

F. Hoffmann-La Roche Ltd

Fresenius Kabi Canada

GSK Plc

AiCuris Anti-infective Cures AG

Chimerix, Inc

Abbott

Bio-Rad Laboratories, Inc

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd

Major Highlights

This report delivers a comprehensive overview of the Cytomegalovirus Infection Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cytomegalovirus Infection Treatment Market. The Cytomegalovirus Infection Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the

latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Drug Type
- 3.2. Snippet by Application
- 3.3. Snippet by Infection
- 3.4. Snippet by Diagnosis Test
- 3.5. Snippet by Route of Administration
- 3.6. Snippet by Distribution Channel
- 3.7. Snippet by End-User
- 3.8. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Prevalence of Viral Infections
 - 4.1.1.2. Rising Prevalence of CMV Retinitis and Congenital CMV infection
 - 4.1.1.3. Growing Government Initiatives for Creating Awareness Regarding Treatments
 - 4.1.1.4. The Growing Demand for Personalized Medicine
 - 4.1.2. Restraints
 - 4.1.2.1. Adverse Effects and Risks Related to Cytomegalovirus Drugs
 - 4.1.2.2. High Cost Associated with the Treatment
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis

- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Unmet Needs
- 5.6. PESTEL Analysis
- 5.7. Patent Analysis
- 5.8. SWOT Analysis

6. COVID-19 ANALYSIS

- 6.1. Analysis of COVID-19
 - 6.1.1. Scenario Before COVID
 - 6.1.2. Scenario During COVID
 - 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During the Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion

7. BY DRUG TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
 - 7.1.2. Market Attractiveness Index, By Drug Type
- 7.2. Cytovene*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Valcyte
- 7.4. Foscarnet
- 7.5. Vistide
- 7.6. Others

8. BY APPLICATION

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 8.1.2. Market Attractiveness Index, By Application
- 8.2. Stem Cell Transplantation*
 - 8.2.1. Introduction

- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Organ Transplantation
- 8.4. Congenital CMV infection
- 8.5. Others

9. BY INFECTION

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
 - 9.1.2. Market Attractiveness Index, By Infection
- 9.2. Retinitis*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Pneumonia
- 9.4. Esophagitis
- 9.5. Colitis
- 9.6. Others

10. BY DIAGNOSIS TEST

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
 - 10.1.2. Market Attractiveness Index, By Diagnosis Test
- 10.2. Serologic Test*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Polymerase Chain Reaction (PCR) Test
- 10.4. Others

11. BY ROUTE OF ADMINISTRATION

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 11.1.2. Market Attractiveness Index, By Route of Administration
- 11.2. Oral*
 - 11.2.1. Introduction
 - 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 11.3. Intravenous

12. BY DISTRIBUTION CHANNEL

12.1. Introduction

12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12.1.2. Market Attractiveness Index, By Distribution Channel

12.2. Hospital Pharmacy*

12.2.1. Introduction

12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

12.3. Retail Pharmacy

12.4. Online Pharmacy

12.5. Others

13. BY END-USER

13.1. Introduction

13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13.1.2. Market Attractiveness Index, By End-User

13.2. Hospitals*

13.2.1. Introduction

13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

13.3. Specialty Clinics

13.4. Homecare

13.5. Others

14. BY REGION

14.1. Introduction

14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

14.1.2. Market Attractiveness Index, By Region

14.2. North America

14.2.1. Introduction

14.2.2. Key Region-Specific Dynamics

14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection

14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test

14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

- 14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 14.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 14.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.2.10.1. U.S.
 - 14.2.10.2. Canada
 - 14.2.10.3. Mexico
- 14.3. Europe
 - 14.3.1. Introduction
 - 14.3.2. Key Region-Specific Dynamics
 - 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
 - 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
 - 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
 - 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 14.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 14.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.3.10.1. Germany
 - 14.3.10.2. UK
 - 14.3.10.3. France
 - 14.3.10.4. Italy
 - 14.3.10.5. Spain
 - 14.3.10.6. Rest of Europe
- 14.4. South America
 - 14.4.1. Introduction
 - 14.4.2. Key Region-Specific Dynamics
 - 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
 - 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
 - 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
 - 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
 - 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 14.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 14.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 14.4.10.1. Brazil
 - 14.4.10.2. Argentina
 - 14.4.10.3. Rest of South America

14.5. Asia-Pacific

14.5.1. Introduction

14.5.2. Key Region-Specific Dynamics

14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection

14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test

14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

14.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

14.5.10.1. China

14.5.10.2. India

14.5.10.3. Japan

14.5.10.4. South Korea

14.5.10.5. Rest of Asia-Pacific

14.6. Middle East and Africa

14.6.1. Introduction

14.6.2. Key Region-Specific Dynamics

14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type

14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection

14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test

14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

14.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

15. COMPETITIVE LANDSCAPE

15.1. Competitive Scenario

15.2. Market Positioning/Share Analysis

15.3. Mergers and Acquisitions Analysis

16. COMPANY PROFILES

16.1. Merck & Co., Inc *

16.1.1. Company Overview

- 16.1.2. Product Portfolio and Description
- 16.1.3. Financial Overview
- 16.1.4. Key Developments
- 16.2. F. Hoffmann-La Roche Ltd
- 16.3. Fresenius Kabi Canada
- 16.4. GSK Plc
- 16.5. AiCuris Anti-infective Cures AG
- 16.6. Chimerix, Inc
- 16.7. Abbott
- 16.8. Bio-Rad Laboratories, Inc
- 16.9. Takeda Pharmaceutical Company Limited
- 16.10. Teva Pharmaceutical Industries Ltd (LIST NOT EXHAUSTIVE)

17. APPENDIX

- 17.1. About Us and Services
- 17.2. Contact Us

I would like to order

Product name: Cytomegalovirus Infection Treatment Market - 2023-2031

Product link: <https://marketpublishers.com/r/C314C95CB99DEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C314C95CB99DEN.html>